Tag: Novartis Pharmaceuticals Corporation

Novartis and The Max Foundation Transform Pioneering Cancer Access Program for People in Lower-Income Countries

Novartis announced a new collaboration with The Max Foundation to support continued access to treatment at no cost for nearly 34,000 current patients with chronic myeloid leukemia (CML), gastrointestinal tumors (GIST) and other rare cancers. The two organizations have been long-time collaborators in providing access to care for patients in…

Novartis Foundation Launches Initiative to Tackle Hypertension in Low-Income Urban Communities

On World Hypertension Day 2017, the Novartis Foundation and its partners, including Intel Corporation, the NCD Alliance, city governments and local partners, announce the launch of Better Hearts Better Cities, an innovative initiative to address the high rates of high blood pressure (hypertension) in low-income urban communities. Rapid urbanization in…

Novartis Acquires Selexys Pharmaceuticals Corporation, SelG1 Antibody for Pain Reduction in Sickle Cell Disease

Novartis (No. 2 on the DiversityInc Top 50 Companies list) announced it has acquired Selexys Pharmaceuticals Corporation, a company specializing in development of therapeutics in certain hematologic and inflammatory disorders. Novartis exercised its right to acquire Selexys following receipt of results of the SUSTAIN study, a Phase II trial evaluating…